Silexion Therapeutics Ltd.
SLXNAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Maxim Group | maintain | Buy | Mar 20, 2025 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-9.10| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-5.17 | $-21.20 | — | — |
| May 12, 2026 | $-8.50 | $-12.90 | — | — |
| Mar 17, 2026 | $-23.85 | $-1.17 | — | — |
| Nov 12, 2025 | $-28.80 | $-34.00 | — | — |
| Aug 12, 2025 | $-43.20 | $-31.50 | — | — |
| May 13, 2025 | $-38.98 | $-33.00 | — | — |
| Mar 18, 2025 | $-115.50 | $-147.00 | — | — |
| Nov 14, 2024 | $-1110.00 | $-1107.00 | — | — |
News
Global Phase 2/3 trial evaluates SIL204 in combination with standard chemotherapy in patients with locally advanced pancreatic cancer
Cayman Islands, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding series E warrants to purchase up to an aggregate of 3,216,928 of the Company's ordinary shares originally issued in August 2026 having a reduced exercise price of …
Translational research demonstrates that SIL204 utilizes native serum lipids to facilitate intracellular delivery and robust KRAS oncogene knockdown
Grand Cayman, Cayman Islands, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that members of its management team will participate in the following industry and investor conferences in September 2026: Oncology & Immunology Innovation Partnering & Licensing Summit Presentation date: September 9, 2026 Location: Hot…
Successfully transitioned SIL204 from regulatory preparation into an active Phase 2/3 clinical program in locally advanced pancreatic cancer, with trial initiation at Tel Aviv Sourasky Medical Center in July 2026 following clinical trial authorizations from regulators in both Israel and Germany
GRAND CAYMAN, Cayman Islands, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the pricing of a public offering of an aggregate of 3,846,161 of the Company's ordinary shares (or ordinary share equivalents) and series E warrants to purchase up to 3,846,161 ordinary at a combined public offering price of…